Intraosseous Vancomycin in Primary Total Hip Arthroplasty - Designing a Protocol
Phase 4
Completed
- Conditions
- VancomycinProsthetic Joint InfectionJoint Diseases
- Interventions
- First Posted Date
- 2019-08-01
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 23
- Registration Number
- NCT04042233
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
Neoadjuvant Atezolizumab in Cutaneous Melanoma
- First Posted Date
- 2019-07-16
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 20
- Registration Number
- NCT04020809
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
Brain Imaging in Men With Lower Urinary Tract Symptoms
Completed
- Conditions
- Voiding Disorders
- Interventions
- Diagnostic Test: Simultaneous functional MRI and urodynamic studiesBehavioral: QuestionnairesOther: Post Void Residual (PVR), Uroflow and Bladder DiaryDiagnostic Test: Urinalysis
- First Posted Date
- 2019-06-19
- Last Posted Date
- 2023-01-05
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 11
- Registration Number
- NCT03991429
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
Ocrelizumab for Psychosis by Autoimmunity
Phase 1
Recruiting
- Conditions
- SchizophreniaSchizo-Affective Type of Psychosis
- Interventions
- Behavioral: Psychosis and cognitive assessmentsBehavioral: Physical and neuro-cognitive evaluationsDiagnostic Test: Safety labs and electrocardiogramBiological: Ocrelizumab infusion
- First Posted Date
- 2019-06-03
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 40
- Registration Number
- NCT03971487
- Locations
- 🇺🇸
Houston Methodist Research Institute, Houston, Texas, United States
Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer
Phase 2
Recruiting
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2019-01-29
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 39
- Registration Number
- NCT03820141
- Locations
- 🇺🇸
Houston Methodist Cancer Center, Houston, Texas, United States
Olaparib in Combination with Vorinostat in Patients with Relapsed/Refractory And/or Metastatic Breast Cancer
Phase 1
Recruiting
- Conditions
- Breast Cancer MetastaticBreast Cancer
- Interventions
- First Posted Date
- 2018-11-15
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 28
- Registration Number
- NCT03742245
- Locations
- 🇺🇸
Houston Methodist Cancer Center, Houston, Texas, United States
Stroke Recovery and Music or No Music
Not Applicable
- Conditions
- Ischemic Stroke
- Interventions
- Other: Music listeningOther: Spoken word (language) listening
- First Posted Date
- 2018-08-01
- Last Posted Date
- 2018-08-01
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 20
- Registration Number
- NCT03608904
- Locations
- 🇺🇸
Houston Methodist, Houston, Texas, United States
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Phase 1
Recruiting
- Conditions
- GlioblastomaAnaplastic Astrocytoma
- Interventions
- Drug: ADV/HSV-tk (gene therapy)
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 62
- Registration Number
- NCT03603405
- Locations
- 🇺🇸
Houston Methodist Neurological Institute, Houston, Texas, United States
Brain Targets in Patients With Bladder Emptying Difficulties
Not Applicable
Completed
- Conditions
- Neurogenic BladderMultiple SclerosisVoiding Dysfunction
- Interventions
- Device: Transcranial Rotating Permanent Magnet Stimulator (TRPMS)
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2023-10-05
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 11
- Registration Number
- NCT03574610
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery
Phase 2
- Conditions
- Prostate CancerHigh-risk Prostate Cancer
- Interventions
- Drug: HSV-TkDrug: ValacyclovirDrug: BicalutamideDrug: Leuprolide AcetateRadiation: Brachytherapy, External beam radiotherapyProcedure: Radical prostatectomy
- First Posted Date
- 2018-05-31
- Last Posted Date
- 2021-04-06
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 60
- Registration Number
- NCT03541928
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath